Clinical Trials | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The facility will accommodate over 1,500 employees
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
Subscribe To Our Newsletter & Stay Updated
